Abstract

The major isoform of Trypanosoma cruzi cysteinyl proteinase (cruzipain) has generated Lys-bradykinin (Lys-BK or kallidin), a proinflammatory peptide, by proteolysis of kininogen. The releasing of this peptide was demonstrated by mass spectrometry, radioimmunoassay, and ileum contractile responses. The kinin-releasing activity was immunoabsorbed selectively by monoclonal antibodies to the characteristic COOH-terminal domain of cruzipain. To determine the hydrolysis steps that account for the kininogenase activity of cruzipain, we synthesized a fluorogenic peptide (o-aminobenzoyl-Leu-Gly-Met-Ile-Ser-Leu-Met-Lys-Arg-Pro-Pro-Gly-Phe-S er-Pro-Phe-Arg389-Ser390-Ser-Arg-Ile-NH2) based on the sequence Leu373 to Ile393 of the human high molecular weight kininogen. The hydrolysis products from this peptide were isolated by high performance liquid chromatography, and Lys-BK was characterized as the major released kinin by mass spectrometry. Intramolecularly quenched fluorogenic peptides spanning the Met379-Lys380 and Arg389-Ser390 bradykinin-flanking sequences were then used to assess the substrate specificity requirements of the parasite-derived protease compared with two COOH-terminal truncated recombinant isoforms (cruzain and cruzipain 2). In contrast to the high catalytic efficiency of parasite-derived cruzipain, the recombinant proteinases cleaved the bradykinin-flanking sites at markedly different rates. In addition, we also demonstrated that cruzipain activates plasmatic prekallikrein, which would be a second and indirect way of the parasite protease to release bradykinin.

Highlights

  • Trypanosoma cruzi, the parasitic protozoan that causes Chagas’ disease, undergoes an obligatory stage of intracellular replication in the mammalian host [1,2,3]

  • Different signaling pathways are triggered in the mammalian cell [4, 5], the process being accompanied by cytosolic-free Ca2ϩ transients in T. cruzi [6]

  • Sequence analysis of some of these variant genes revealed that non-conservative amino acid substitutions tend to cluster in the catalytic domain, some of the changes being localized to positions that could conceivably influence the subsite specificity

Read more

Summary

The abbreviations used are

Lys-BK, Lys-bradykinin; Abz, o-aminobenzoic acid; Abz-(Leu373-Ile393)-hKng-NH2, human kininogen segment Abz-LGMISLMKRPPGFSPFRSSRI-NH2; MALDI-TOF, matrix-assisted laser desorption ionization time of flight; Z, benzyloxycarbonyl; MCA, methylcoumarin amide; E-64, trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane; EDDnp, N-[2,4-dinitrophenyl]ethylenediamine; HMWK, high molecular weight kininogen; LMWK, low molecular weight kininogen; HPLC, high performance liquid chromatography. Kininogenase Activity of Cruzipain kininogen labeled at the NH2 terminus with o-aminobenzoic acid (Abz-(Leu373-Ile393)-hKng-NH2) and related internally quenched fluorogenic peptides. We used synthetic substrates based on the NH2-terminal and COOH-terminal flanking regions of bradykinin in human kininogen to compare the substrate specificity requirements of two recombinant isoforms, namely cruzain and cruzipain 2, with the parasitederived cruzipain. We demonstrated that cruzipain was able to act via contact phase activation cascade by converting plasma prekallikrein into active kallikrein

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call